JP4642242B2 - 細胞接着の阻害剤としての新規のグアニジン誘導体 - Google Patents

細胞接着の阻害剤としての新規のグアニジン誘導体 Download PDF

Info

Publication number
JP4642242B2
JP4642242B2 JP2000598485A JP2000598485A JP4642242B2 JP 4642242 B2 JP4642242 B2 JP 4642242B2 JP 2000598485 A JP2000598485 A JP 2000598485A JP 2000598485 A JP2000598485 A JP 2000598485A JP 4642242 B2 JP4642242 B2 JP 4642242B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
cycloalkyl
formula
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000598485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002536438A5 (https=
JP2002536438A (ja
Inventor
ペイマン アヌシルヴァン
クノル ヨッヘン
ショイネマン カールハインツ
ウィリアム ウィル デイビッド
カルニアトー ドニ
グールベスト ジャンフランソワ
ガデック トマス
キャサリン ボダリー セイラ
Original Assignee
アヴェンティス ファルマ ドイチェラント ゲーエムベーハー
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴェンティス ファルマ ドイチェラント ゲーエムベーハー, ジェネンテック， インコーポレイテッド filed Critical アヴェンティス ファルマ ドイチェラント ゲーエムベーハー
Publication of JP2002536438A publication Critical patent/JP2002536438A/ja
Publication of JP2002536438A5 publication Critical patent/JP2002536438A5/ja
Application granted granted Critical
Publication of JP4642242B2 publication Critical patent/JP4642242B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2000598485A 1999-02-13 2000-02-04 細胞接着の阻害剤としての新規のグアニジン誘導体 Expired - Lifetime JP4642242B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99102916.6 1999-02-13
EP99102916A EP1028114A1 (en) 1999-02-13 1999-02-13 Novel guanidine derivatives as inhibitors of cell adhesion
PCT/EP2000/000895 WO2000047564A1 (en) 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion

Publications (3)

Publication Number Publication Date
JP2002536438A JP2002536438A (ja) 2002-10-29
JP2002536438A5 JP2002536438A5 (https=) 2007-01-11
JP4642242B2 true JP4642242B2 (ja) 2011-03-02

Family

ID=8237555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000598485A Expired - Lifetime JP4642242B2 (ja) 1999-02-13 2000-02-04 細胞接着の阻害剤としての新規のグアニジン誘導体

Country Status (11)

Country Link
US (1) US6340679B1 (https=)
EP (2) EP1028114A1 (https=)
JP (1) JP4642242B2 (https=)
AT (1) ATE273285T1 (https=)
AU (1) AU768206B2 (https=)
CA (1) CA2371789C (https=)
DE (1) DE60012890T2 (https=)
ES (1) ES2225086T3 (https=)
IL (1) IL144725A0 (https=)
MX (1) MXPA01008072A (https=)
WO (1) WO2000047564A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
CZ2002518A3 (cs) 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
WO2009128934A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH08504194A (ja) 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
NZ290008A (en) 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
ATE308981T1 (de) 1995-08-14 2005-11-15 Scripps Research Inst Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
EP0907637A1 (de) * 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalanin-derivate als integrin-inhibitoren
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
YU47200A (sh) 1998-01-23 2002-11-15 Aventis Pharma Deutschland Gmbh. Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije

Also Published As

Publication number Publication date
EP1155003A1 (en) 2001-11-21
CA2371789C (en) 2009-04-14
AU768206B2 (en) 2003-12-04
EP1155003B1 (en) 2004-08-11
ATE273285T1 (de) 2004-08-15
IL144725A0 (en) 2002-06-30
AU2669900A (en) 2000-08-29
MXPA01008072A (es) 2002-07-30
US6340679B1 (en) 2002-01-22
WO2000047564A1 (en) 2000-08-17
DE60012890D1 (de) 2004-09-16
EP1028114A1 (en) 2000-08-16
JP2002536438A (ja) 2002-10-29
CA2371789A1 (en) 2000-08-17
ES2225086T3 (es) 2005-03-16
DE60012890T2 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
JP4642242B2 (ja) 細胞接着の阻害剤としての新規のグアニジン誘導体
KR20010033281A (ko) 골흡수 억제제 및 비트로넥틴 수용체 길항제인 신규 아실구아니딘 유도체
US6747148B2 (en) Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6660728B2 (en) Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
JP2002501054A (ja) 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体
US6747016B1 (en) Substituted purine derivatives as inhibitors of cell adhesion
US6762190B2 (en) Thienylalanine derivatives as inhibitors of cell adhesion
JP4550286B2 (ja) 新規なアシルグアニジン誘導体、それらの製造方法、薬剤としてのそれらの使用及びそれらを含有する製薬組成物
US6838453B2 (en) Antagonist derivatives of the vitronectin receptor
JP4522586B2 (ja) 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用
JP2003532732A5 (https=)
US7259159B2 (en) Guanidino derivatives as inhibitors of cell adhesion
CZ20002246A3 (cs) Derivát acylguanidinu jako inhibitor resorpce kostí jako antagonist vitronektinového receptoru
CZ20002672A3 (cs) Sulfonamidové deriváty jako inhibitory kostní resorpce a jako inhibitory buněčné adheze

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100618

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101201

R150 Certificate of patent or registration of utility model

Ref document number: 4642242

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term